title: The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study.
abstract: BACKGROUND
  The behavioral and psychological symptoms of dementia present a major challenge in the management of these patients. There is no Food and Drug Administration-indicated medication for the management of these symptoms. Even though atypical antipsychotics are considered safer than conventional antipsychotics, safety concerns have emerged.
  
  
  BACKGROUND
  The FDA has issued warnings regarding the cardiac and metabolic side effects, cerebrovascular events, and, most recently, mortality risk. This study was conducted in 2003 when physicians were notified of the cerebrovascular risks of risperidone. Since then, similar warnings have been issued for olanzapine and aripiprazole.
  
  
  METHODS
  The medical records of 58 elderly dementia patients who were taking risperidone and were abruptly switched to olanzapine were reviewed. Clinical Global Impressions scale at assigned retrospectively at switch, and weeks 4-6 assessed treatment.
  
  
  RESULTS
  Baseline and follow-up Clinical Global Impressions scale scores were essentially unchanged. Adverse events were mild to moderate in severity. Mean risperidone dose at switch was 1.54 mg/day (range: 0.25-6 mg/day). Mean olanzapine dose after the switch was 5.69 mg/day (range: 2.52-27.5 mg/day).
  
  
  CONCLUSIONS
  Most of the 58 patients were switched from risperidone to olanzapine without any deterioration in their clinical status. Even though it is generally not recommended in elderly patients, abrupt switching did not have any negative consequences in this group of patients.
authors.affiliation: Department of Psychiatry, Peninsula Hospital Center, USA. sdanan@ehs.org
authors.forename: Subramoniam
authors.initials: S
authors.lastname: Madhusoodanan
authors.forename: Olivera
authors.initials: O
authors.lastname: Bogunovic
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D015897:Comorbidity; D015140:Dementia, Vascular / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D005500:Follow-Up Studies; D006707:Homes for the Aged; D006801:Humans; D008297:Male; D009735:Nursing Homes; D000077152:Olanzapine; D011618:Psychotic Disorders / Q000175:diagnosis / Q000188:drug therapy; D012189:Retrospective Studies; D012307:Risk Factors; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine